Bali Muralidhar, Director at Reneo Pharmaceuticals, Inc. (RPHM), bought 12,357 shares at $9.25 ($114K) on 2021-06-03, disclosed to the SEC on 2021-06-07.
Open-market purchase of $114k RPHM by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.25 | 12,100 | $112K | 97.9% |
| 2 | $9.42 | 257 | $2K | 2.1% |
| Total | $9.25 avg | 12,357 | $114K | 100% |
| Filing → |
| RPHM | BUY | 2021-06-25 | $384K | — | Filing → |
| RPHM | BUY | 2021-06-23 | $845K | — | Filing → |
| RPHM | BUY | 2021-06-10 | $315K | — | Filing → |